Alimentiv Inc.

Address: 100 Dundas Street Suite 200

Sponsor Overview

assignment

Specializations

Inflammatory Bowel Disease Management

Alimentiv Inc. concentrates on advancing therapeutic strategies for inflammatory bowel diseases, with particular emphasis on ulcerative colitis and Crohn's disease. The organisation investigates optimal treatment targets in patients experiencing moderate to severe disease activity, exploring comprehensive approaches that extend beyond traditional symptomatic control.

Ulcerative Colitis Treatment Optimization
Moderately to Severely Active Crohn's Disease
Treatment Target Comparison Studies

The research portfolio addresses the clinical challenge of determining the most effective therapeutic endpoints, comparing conventional symptomatic remission targets against more rigorous multi-dimensional treatment goals that incorporate tissue healing and biological markers.

Mucosal and Transmural Healing

A distinctive focus area involves investigating the therapeutic value of achieving complete bowel wall healing across all tissue layers. The sponsor examines whether transmural healing represents a superior treatment objective compared to partial tissue recovery in inflammatory bowel disease management.

Endoscopic Remission Assessment
Histological Remission Evaluation
Transmural Mucosal Healing

Research initiatives explore comprehensive healing outcomes that encompass endoscopic assessment, histological examination, and evaluation of deeper intestinal wall structures, seeking to establish optimal therapeutic benchmarks for long-term disease control.

Corticosteroid-Free Remission Strategies

Alimentiv Inc. prioritises the development of treatment approaches that achieve sustained disease control without ongoing corticosteroid dependency. The research programme evaluates various remission targets while specifically requiring freedom from corticosteroid therapy as a fundamental outcome criterion.

Steroid-Free Clinical Remission
Biomarker-Guided Treatment Targets
Long-Term Complication Prevention

Studies incorporate biomarker remission alongside clinical and structural healing parameters, investigating whether comprehensive multi-factorial treatment targets reduce disease-related complications and improve long-term patient outcomes over extended follow-up periods.

Trial Name	Country	Status
Evaluation of Transmural Healing as a Treatment Target in Moderately to Severely Active Crohn's Disease Using Upadacitinib, Risankizumab, and Ustekinumab	Belgium Denmark France Germany Italy Poland Portugal The Netherlands	Recruiting
Evaluation of Vedolizumab in Achieving Corticosteroid-Free Remission in Patients with Moderately to Severely Active Ulcerative Colitis: A Randomized Controlled Trial	Belgium France Italy Poland The Netherlands	Not Recruiting